

Anteris Technologies Ltd

19:48 02 Sep 2018

Admedus secures strategic cornerstone investor from Hong Kong

Admedus Ltd (ASX:AHZ) continues to build its relationship with strategic investor and shareholder Star Bright Holding Ltd, who will increase its holding to 19.99%.

Star Bright has agreed to subscribe for up to an additional 68.9 million shares in Admedus as part of a share placement raising up to \$7.7 million.

Admedus has also entered into a \$5 million unsecured loan facility with Star Bright for the purposes of repaying the existing, higher interest loan from Partners For Growth.

READ: Admedus extends successful distribution deal for medication delivery pumps

Admedus's CEO Wayne Paterson said: "Having already indicated a commitment to provide \$18 million of long-term funding to our Immunotherapies business, and having participated in the last capital raise, Star Bright have demonstrated their belief and interest in our company.

"Madam Zhang, and her company, are aligned with our mission to deliver clinically superior solutions to patients and we welcome a significant strategic investor onto our register."

A gateway to China

Star Bright is a Hong Kong-based private investment company 100% owned by Madam Zhang Lishan whose business interests are primarily global asset and equity investments,

Star Bright recognises the potential of Admedus' ADAPT technology to deliver tangible benefits for the global medical community and its ability to improve the lives and health outcomes of patients.

As well as their equity investment, Star Bright has indicated their interest in helping to establish an Admedus commercial base in China in the near term.

Star Bright's shares will be issued in two tranches

The first tranche of 42.59 million shares priced at 10 cents raising \$4.25 million was issued on 22 August 2018.


The second tranche of 26.28 million shares will be priced at 13.03 cents will raise an addition \$3.42 million and is yet to be issued.

Notably, Star Bright has agreed not to sell the placement shares for 12 months

Price: 3.8

Market Cap: \$22.46 m

1 Year Share Price Graph



Share Information

Code: AVR

Listing: ASX

52 week High Low
7.5 3.03

Sector: Pharma & Biotech

Website: anteristech.com

Company Synopsis:

Anteris Technologies Ltd (ASX:AVR) is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients.

action@proactiveinvestors.com

from their issue date.

Beneficial loan facility terms

The new Star Bright \$5 million unsecured loan facility has a three year term on a 5% annual coupon payable quarterly with the potential for shares to be issued in lieu of the coupon payment.

The previous loan facility has now been repaid and had a much higher interest rate of 11.75%.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).